Microparticle Capture Ligand Biomarker Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for measuring soluble and secreted cytokines and other analytes in serum and plasma face limitations, such as poor sensitivity and inability to perform high-throughput multiplex analyses, particularly due to dilution effects in existing cytometric bead-based assays and ELISA techniques.
Innovation Solution
The method involves co-culturing cells with microparticles that have capture ligands, allowing for the binding of biomarkers produced by cells, followed by detection using flow or mass cytometry to determine the proportion and number of cells producing the biomarkers and the level of biomarkers secreted, thereby overcoming dilution issues and enabling more precise analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If ELISA or Cytometric Bead Array (CBA) is used to measure secreted analytes, then quantitative measurement is achieved, but sensitivity is poor due to dilution by diffusion in the supernatant
Solution Approach 1:
The patent uses magnetic beads coated with capture antibodies as intermediaries to capture analytes directly from cell culture supernatant. These beads serve as a solid phase mediator that concentrates the analyte, preventing dilution effects and enabling sensitive detection through flow cytometry or magnetic-activated cell sorting (MACS).
Solution Approach 2:
The patent segments the measurement process into distinct steps: (1) cell culture with secreted analytes, (2) addition of magnetic beads with capture antibodies, (3) magnetic separation to isolate bead-analyte complexes from cells and supernatant, and (4) detection using flow cytometry or other methods. This segmentation allows the analyte to be concentrated on the bead surface rather than diluted in the supernatant.
2Adaptability or versatility
If conventional cytometric bead-based assays are used, then multiplex analysis capability is provided, but throughput is limited and sensitivity is reduced due to dilution effects
Solution Approach 1:
The patent employs a universal magnetic bead platform where different bead populations can be coated with various capture antibodies for different analytes. The same magnetic separation and detection methodology applies to all analytes, enabling high-throughput multiplex analysis across multiple targets simultaneously.
Solution Approach 2:
The patent replaces conventional flow cytometry-based bead array systems with a magnetic separation approach followed by flow cytometry or other detection methods. The magnetic separation step enables rapid isolation of bead-analyte complexes from cell cultures, significantly improving throughput compared to conventional methods that require direct analysis of supernatant.
3Measurement precision
If ELISA-based assays are used for quantitative analysis of cytokines, then standardization is achieved, but high throughput multiplex analyses are not well suited and sensitivity is poor
Solution Approach 1:
The patent changes the detection parameter from measuring analyte concentration in diluted supernatant (ELISA) to measuring the physical presence and quantity of magnetic beads carrying captured analytes. This parameter change enables both high sensitivity (through bead concentration) and high throughput (through flow cytometric or magnetic sorting-based quantification of multiple bead populations).
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances sensitivity and allows for multiplex analysis, providing accurate quantitation of biomarkers without the need for specialized equipment or radioactivity, offering a more effective method for evaluating cellular responses and immune function.
Implementation Method 1
a biomarker produced by the cell is bound (e.g., immediately bound) by the capture ligand
Implementation Method 2
detecting (e.g., by flow or mass cytometry) complexes that include the microparticle, the capture ligand, the biomarker, and a detection reagent
Implementation Method 3
The CBA system from BD Biosciences relies on different fluorescent intensities of a single fluorophore to accomplish multiplexing
Implementation Method 4
detecting (e.g., by flow or mass cytometry) complexes that include the microparticle, the capture ligand, the biomarker, and a detection reagent
Data Source
AI summary
Aspects of the present disclosure include methods that include co-culturing a cell and a microparticle that includes a capture ligand, in a culture medium under conditions in which a biomarker produced by the cell is bound by the capture ligand. Such methods may further include detecting (e.g., by flow or mass cytometry) complexes that include the microparticle, the capture ligand, the biomarker, and a detection reagent. The methods may further include determining the proportion or number of cells among a heterogeneous cell population that produced the biomarker and/or the level of biomarker secreted by such cells. Compositions, systems and kits are also provided.